PIA
ABUS icon

Piedmont Investment Advisors’s Arbutus Biopharma ABUS Stock Holding History

Piedmont Investment Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-613
Closed -$4K – 1042
2018
Q2 		$4K Buy
+613
New +$3.65K ﹤0.01% 2199

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Piedmont Investment Advisors's ABUS Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Arbutus Biopharma (ABUS) in Q3 2018, closing a stake of 613 shares — an estimated $4K sold.

Piedmont Investment Advisors first reported a position in ABUS in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 88 funds tracked by Wall St. Rank hold ABUS as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Arbutus Biopharma position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 613 Arbutus Biopharma shares in Q3 2018, an estimated $4K.
  • Piedmont Investment Advisors first reported a position in Arbutus Biopharma in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Arbutus Biopharma position peaked at $4K in Q2 2018.
  • 88 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.